ONLINE SUBMISSION
  March, 2009

Dengue Fever with Hepatitis E and Hepatitis A infection

  Javed Yakoob, Wasim Jafri, Shaheer Siddiqui, Mehmood Riaz  ( Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan. )
 

Abstract
Infection with dengue viruses produces a spectrum of clinical illness ranging from a nonspecific viral syndrome to severe and fatal haemorrhagic disease. Important risk factors include the strain and serotype of the infecting virus, as well as the age, immune status, and genetic predisposition of the patient. The teaching point in this case study was Dengue fever which occurred concomitantly with Hepatitis A and Hepatitis E virus infection.

Introduction

Jaundice follows due to a variety of causes including hepatitis A, B, C, D, and E viral infections, alcohol abuse, medications and toxins. Hepatitis E virus (HEV) and hepatitis A virus (HAV) are endemic in South Asia.1 Dengue fever (DF) is a mosquito-borne virus infection, caused by four distinct viruses (serotypes 1 to 4) that are closely related antigenically. Dengue virus serotype 3 is responsible for most of the DF cases in Karachi, Pakistan.2 There is no treatment of Dengue fever (DF). However, dengue fever shock syndrome requires a supportive treatment.3


Case Report

A 17 year old girl was admitted in September 2007 with jaundice for one month associated with fever for ten days and altered consciousness since one day. There was no significant past history. Patient had paracetamol and antimalarials for the last ten days. On examination, she was jaundiced and drowsy; Glasgow coma scale (GCS) was 8/15 with a pulse 108/min, blood pressure 109/73 mm Hg and temperature of 102ºF. Systemic examination was normal, besides a palpable spleen. The labs on admission demonstrated a haemoglobin of 10 (range 11.1-14.5) gm/dl, haematocrit 34.3% (range 35.4-42.0), white cell count 3.2 (range 2.0-10.0) with neutrophil 84% (range 40-75), platelet 183 x109/L (range 150-400); malarial parasite was not seen on film; prothrombin time (PT) 23 (range 10-15 seconds), activated plasma thrombin time (APTT) 38.4 sec(range 25-35 seconds), bilirubin 22 (range 0.25-1.0) mg/dl, alanine transaminase (ALT) 330 (range 3-33) I.U/L, aspartate transaminase (AST) 220 (range 18-32) I.U/L; alkaline phosphatase (ALP) 518 (range 31-141) I.U/L, gamma glutamate transaminase (GGT) 33 (range 1-37) I.U/L, sodium 127 (range 136-148) mmol/L, potassium 2.5 mg (range 3.6-5.0) mmol/L, albumin 1.9 g/dl, serum amylase 125 (range 25-125) U/L, lactic dehydrogenase (LDH) 705 mg, magnesium 1.8 (range 1.9-2.5) mg/dl. Plasmodium falciparum and Plasmodium Viva were negative by immunochromatographic test (ICT) detecting malaria antigen. She was admitted in intensive care unit for grade III Hepatic encephalopathy and treated with IV fluid and lactulose. She stabilized haemodynamically over next two days and her WBC count reduced to 15.3, PT 27, ALT 59, K 3.0 mmol/L. Patient recovered from Hepatic encephalopathy after 4 days. Serology was positive for HEV and HAV IgM antibodies. Hepatitis B virus s Antigen (HBsAg), Hepatitis B core IgM, Hepatitis C virus antibody and HEV virus IgG were negative. Her chest x-ray and abdominal ultrasound were normal. Blood cultures were negative. Antinuclear antibody, anti-smooth muscle antibody and anti-mitochondrial antibody screen were negative but Coomb's test was positive. Serum ceruloplasmin and Urinary copper were in the normal range. She was discharged home after two days after being stabilized, on steroids, proton pump inhibitor and folic acid for haemolytic anemia. Patient’s serology for DF IgM was positive.


Discussion

In this case, the dengue infection occurred concurrently while the patient was also suffering from HEV and HAV. Anti-dengue IgM detectable by IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) appears in half of the patients with a primary infection while they are still febrile; in the other half, it appears within 2-3 days of defervescence.4 Anti-dengue IgM levels are detectable in about 30% of patients 2 months after the onset of symptoms5 In this case, also, dengue fever was positive on repeating the test. This is a common observation by physicians actively involved in the management of patients with dengue fever.5 Symptoms and signs of dengueinfection, especially during the acute phase of illness, are difficult to distinguish from other diseases such as malaria and typhoid, which were negative in this case.6 This patient also had a positive Coomb's test which is known to be associated with acute HEV, HAV and DV infection.

Dengue fever is one of the serious emerging infection in several cities of Pakistan.2 There are previous case reports of DF occurring concomitantly with other viral, bacterial and parasitic infections.6 The cases of DF occur in the months immediately following rainy seasons. It is known that detectable levels of anti-dengue antibodies appear after several days of fever. Persons never previously infected with a flavivirus, nor immunized with a flavivirus vaccine, show a primary antibody response when infected with a dengue virus. Once detectable, IgM levels rise quickly and appear to peak about 2 weeks after the onset of symptoms, anti-dengue IgG appears afterwards. Anti-dengue IgM is conclusive for a recent dengue infection.4

The cells of macrophage-lineage, interstitial dendritic cells (DC) and Langerhan cell (LC) constitute the first line of the innate host defense against invading DV in skin where it replicates after the initial bite by infected mosquito. Macrophages are the principal cells to replicate DV which impairs their function and increases severity of the damage to the body.7 The impact of DV infection on innate immunity is the determining factor. Early activation of natural killer (NK) cells and type-I interferon dependent immunity may limit viral replication at the early stages of DV infection.8 A successful challenge to virus infection requires that a balance between the induction of efficient anti-viral effector mechanisms and the avoidance of detrimental tissue damage. The increased level of progesterone and estrogens in women are also known to directly influence viral replication and viral gene expression through their effects on viral regulatory elements.8 The potential risk factor for enhanced viral replication/expression in women, include malnutrition and folate deficiency which increases the incidence of the multiple viral infection and/or increased viral load.9 A selective high susceptibility could be associated with the genes of the major histocompatibility complex (MHC), which has a strong effect on immune response to viral antigens.9 It is possible that a specific HLA allele(s) or haplotype(s) prevalent in women might influence the persistence infection.10 Dendritic cells play a central role in promoting cell-mediated immunity. Infected DCs fail to respond to tumour necrosis factor alpha as an additional maturation stimulus and were found to be apoptotic.10

Conclusion

Any patient with prolonged fever should alert the physician of other serious infections such as dengue fever, which may be potentially fatal if not promptly recognized and treated. From the epidemiology point of view, family members often manage DF symptomatically, and consequently the diagnosis of dengue infection will be overlooked, remaining unreported. The case shows that concurrent infections with HEV, HAV and DV can possibly change the clinical spectrum of the disease. This combination is rare but for good outcome, careful overall assessment is required to help avoid unnecessary delay in the diagnosis of illness.


Competing Interests

The authors have no competing interests.


Consent
Written consent was obtained from the patient for publication of this short report.

References

1. Isaacson P, Norton A. Extranodal lymphoma in miscellaneous sites. In: Isaacson P, Norton A eds. Extranodal Lymphomas, New York: Churchill Livingstone 1994; pp 289-98.
2. Heyning FH, Hogendoorn PC, Kramer MH, Hermans J, Kluin-Nelemans JC, Noordijk EM, et al. Primary non-Hodgkin's lymphoma of bone: aclinicopathological investigation of 60 cases. Leukemia 1999; 13:2094-8.
3. Bayrakci K, Yildiz Y, Saglik Y, Altay M, Ogut H, Samur M, et al. Primary lymphoma of bones. Int Orthop 2001; 25:123-6.
4. Zinzani PL, Carrillo G, Ascani S, Barbieri E, Tani M, Paulli M, et al. Primary bone lymphoma: experience with 52 patients. Haematologica 2003; 88: 280-5.
5. Barbieri E, Cammelli S, Mauro F, Perini F, Cazzola A, Neri S, et al. Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for stage I and stage II. Int J Radiat Oncol Biol Phys 2004; 59:760-4.
6. Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106:2652-6.
7. Ostrowski ML, Unni KK, Banks PM, Shives TC, Evans RG, O'Connell MJ, et al. Malignant lymphoma of bone. Cancer 1986; 58:2646-55.
8. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, et al. Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 2007; 37:216-23.
9. Brousse C, Baumelou E, Morel P. Primary lymphoma of bone: a prospective study of 28 cases. Joint Bone Spine 2000; 67: 446-51.
10. Doll C, Wulff B, Rossler J, Schaper J, Havers W. Primary B-cell lymphoma of bone in children. Eur J Pediatr 2001; 160: 239-42.


News & Events

Dear Friends and Colleagues,
May you have a very Happy EID with your friends and Family.
May all of us be Blessed with peace and tranquility.
Let us all jointly say a prayer for all troubled persons all over the world
Warm regards,
Dr. Fatema Jawad
Editor-in-chief,
Journal of Pakistan Medical Association, Karachi
President, PAME
Pakistan Association of Medical Editors



WHO/GOARN Request for technical assistance for Cholera Control in Northern Iraq

Request for assistance

WHO is requesting assistance from GOARN partners to identify the following cholera and diarrhoeal diseases expertise to support the Ministry of Health of Iraq in cholera risk assessment and immediate preparedness activities to improve the health outcomes of the Syrian refugees current living in camps in the Kurdistan region of Iraq.

  • two (2) epidemiologists
  • two (2) clinical management experts
  • one (1) environmental health expert (WATSAN)
  • one (1)laboratory expert

Duration

6 day mission starting 13 June 2014 (this excludes travel time).

Location

Northern Iraq (Kurdistan region).

Language requirements

All candidates must be fluent in English- written, spoken and comprehension. Fluency in Arabic is an asset. Knowledge, abilities and skills All candidates are expected to demonstrate the following

  • Ability to conceptualize and promote innovative strategies and policies.
  • Ability to communicate and write in a clear concise manner, and to develop effective guidelines.
  • Excellent negotiation and interpersonal skills complemented by ability to motivate and lead others and to promote consensus. Tact, discretion and diplomacy
  • Demonstrated ability for project appraisal, project management, monitoring and evaluation and project impact assessment.
  • Ability to work with host governments and their agents, INGOs and national NGOs an advantage.
  • Proven experience of managing a large workload and multiple priorities.
  • Ability to work in difficult conditions.

Support to the mission

WHO/GOARN will cover the travel and per diem (to cover daily expense in the field) expenses for the duration of their mission. GOARN missions do NOT offer salary, consultancy fees or any other form of remuneration.

WHO will provide appropriate logistics support for the field mission. Pre-deployment orientation/training may be required at WHO.

Partners offers of assistance

Partners are requested to reply with offers of assistance, together with CVs and details of the availability of staff for this mission by email to goarn@who.int latest by 30 May 2014. Details of all offers from partners and eventual deployments will be maintained on the GOARN SharePoint.

Operational Contacts

Mamunur Malik WHO EMRO malikm@who.int

William Perea WHO HQ pereaw@who.int

Patrick Drury GOARN druryp@who.int



News



Index



Supplement